300039.SZ SHZ
Shanghai Kaibao Pharmaceutical CO.,Ltd
1W: +0.0%
1M: -2.8%
3M: +18.6%
YTD: -18.8%
1Y: -19.9%
3Y: -18.3%
5Y: +14.0%
¥5.30 ($0.79)
+0.15 (+2.91%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$279M
-27.1% ▼
5Y CAGR: -3.5%
Capital Expenditures
$141M
-383.3% ▼
5Y CAGR: +55.5%
Free Cash Flow
$138M
-60.9% ▼
5Y CAGR: -15.4%
Dividends Paid
$105M
-66.7% ▼
Buybacks
$0
+0.0% ▲
Net Change in Cash
$146M
+20.6% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $106M | $140M | $190M | $327M | $375M |
| Depreciation & Amort. | $41M | $34M | $32M | $38M | $36M |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | $104M | -$49M | $136M | $29M | -$119M |
| Other Non-Cash Items | -$82K | $2M | $19M | -$3M | -$13M |
| Operating Cash Flow | $251M | $126M | $376M | $383M | $279M |
| — Investing Activities — | |||||
| Capital Expenditures | -$14M | -$43M | -$32M | -$29M | -$141M |
| Acquisitions (Net) | -$4M | -$15M | $269K | $29K | $0 |
| Investment Purchases | -$1.8B | -$2.4B | -$1.7B | -$2.0B | -$1.9B |
| Investment Sales | $2.1B | $2.4B | $1.7B | $2.0B | $1.9B |
| Other Investing | -$251M | -$65M | -$303M | -$169M | $112M |
| Investing Cash Flow | $65M | -$84M | -$285M | -$199M | -$33M |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | -$38M | $0 | $0 | $3M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$105M | -$31M | -$52M | -$63M | -$105M |
| Other Financing | $35M | $0 | $0 | $0 | $2M |
| Financing Cash Flow | -$69M | -$69M | -$52M | -$63M | -$99M |
| Net Change in Cash | $246M | -$27M | $39M | $121M | $146M |
| Cash End of Period | $303M | $276M | $314M | $436M | $582M |
| Free Cash Flow | $237M | $84M | $345M | $354M | $138M |